Pharmaxis’ CF Drug Bronchitol Gets Thumbs Down From FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members said pediatric efficacy and safety concerns precluded approval of dry powder mannitol for the broad indication of improving pulmonary function in cystic fibrosis patients ages six years and older.